# Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers

> **NCT01871454** · PHASE2 · UNKNOWN · sponsor: **University of Louisville** · enrollment: 59 (estimated)

## Conditions studied

- Non-small Cell Lung Cancers

## Interventions

- **RADIATION:** stereotactic ablative radiotherapy (SABR)
- **DRUG:** Pentoxifylline

## Key facts

- **NCT ID:** NCT01871454
- **Lead sponsor:** University of Louisville
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-10
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2024-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01871454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01871454, "Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01871454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*